GoInVivo™ is our line of functionally-validated bulk purified antibodies. For researchers interested in no-hassle bulk quantities of biofunctional antibodies for mouse injection or human ex vivo studies, GoInVivo™ provides the best solution at exceptional prices.

GoInVivo™ products focus on targeting immune checkpoints. Tumor cells can express high levels of these checkpoint receptors, shutting down immune responses and taking advantage of the lack of inflammation. Learn more about these interactions with our Immunotherapy Webpage.

GoInVivo™ features

  • Flow cytometry quality testing
  • Super low endotoxin, ≤ 1.0 EU/mg
  • Low aggregation, < 3%
  • Pathogen-free
  • Bulk sizing (5 mg, 25 mg, 50 mg, 100 mg, 500 mg, 1 g sizes)
  • Concentration between 1 mg/ml and 3 mg/ml
  • Custom sizes available
  • Sodium azide and preservative-free
In addition, some of our antibodies are validated in functional assays, including anti-human PD-1 (clone EH12.2H7). All GoInVivo™ reagents will be validated by functional assays.
Anti-human PD-1 inhibits the binding of PD-L1. The graphs show two sets of data. First, recombinant human PD-L1-Fc binds to immobilized human PD-1-Fc that has been coated overnight on a 96-well plate (Cyan lines). PD-1-Fc was coated at 1 µg/mL, and increasing concentrations of PD-L1-Fc (cyan diamonds) or paired PBS wells (cyan circles) were incubated overnight. The bound recombinant PD-L1-Fc was detected using biotin anti-human PD-L1 and Avidin HRP, followed by TMB. After verifying that PD-L1-Fc binds to immobilized PD-1-Fc, a second experiment was performed in which the coated PD-1-Fc was pre-incubated with increasing concentrations of anti-human PD-1 (clone EH12.2H7, purple squares) or isotype control (clone MOPC-21, purple circles), followed by incubation with a fixed concentration of PD-L1 (1 µg/mL). Clone EH12.2H7 inhibits PD-1/PD-L1 interaction in a dose dependent manner.

GoInVivo™ products are tested to be free of the following pathogens based on the origin of the antibody. Pathogen-free is defined based on IDEXX BioResearch’s IMPACT test (PCR-based screening). For detailed information regarding the sensitivity of the assays please contact BioLegend Technical Service: tech@biolegend.com


Remember me
Forgot your password? Reset Password
Request an Account